Cephalon has a three-year period of marketing exclusivity for FENTORA that extends until September 2009. Additionally, the method of use patents described above expire in 2019.

About Cephalon, Inc.

Founded in 1987, Cephalon, Inc. is an international biopharmaceutical company dedicated to the discovery, development and commercialization of innovative products in four core therapeutic areas: central nervous system, pain, oncology and addiction. A member of the Fortune 1000, Cephalon currently employs approximately 3,000 people in the United States and Europe. U.S. sites include the company's headquarters in Frazer, Pennsylvania, and offices, laboratories or manufacturing facilities in West Chester, Pennsylvania, Salt Lake City, Utah, and suburban Minneapolis, Minnesota. The company's European headquarters are located in Maisons-Alfort, France.

The company's proprietary products in the United States include: PROVIGIL(R) (modafinil) Tablets [C-IV], TREANDA(R) (bendamustine hydrochloride), FENTORA, TRISENOX(R) (arsenic trioxide) injection, AMRIX(R) (cyclobenzaprine hydrochloride extended-release capsules), VIVITROL(R) (naltrexone for extended-release injectable suspension), GABITRIL(R) (tiagabine hydrochloride), NUVIGIL(TM) (armodafinil) Tablets [C-IV] and ACTIQ(R) (oral transmucosal fentanyl citrate) [C-II]. The company also markets numerous products internationally. Full prescribing information on its U.S. products is available at http://www.cephalon.com or by calling 1-800- 896-5855.

In addition to historical facts or statements of current condition, this press release may contain forward-looking statements. Forward-looking statements provide Cephalon's current expectations or forecasts of future events. These may include statements regarding anticipated scientific progress on its research programs; development of potential pharmaceutical products; interpretation of clinical results; prospects for regulatory approval; manufacturing development and capabilities; legal matters, including whether the company will initiate a patent infringement lawsuit against Watson; market prospects for its products; sales, adjusted net income and basic adjusted income per common share guidance; and other statements regarding matters that are not historical facts. You may identify some of these forward-looking statements by the use of words in the statements such as "anticipate," "estimate," "expect," "project," "intend," "plan," "believe" or other words and terms of similar meaning. Cephalon's performance and financial results could differ materially from those reflected in these forward-looking statements due to general financial, economic, regulatory and political conditions affecting the biotechnology and pharmaceutical industries as well as more specific risks and uncertainties facing Cephalon such as those set forth in its reports on Form 8-K, 10-Q and 10-K filed with the U.S. Securities and Exchange Commission. Given these risks and uncertainties, any or all of these forward-looking statements may prove to be incorrect. Therefore, you should not rely on any such factors or forward-looking statements. Furthermore, Cephalon does not intend to update publicly any forward-looking statement, except as required by law. The Private Securities Litigation Reform Act of 1995 permits this discussion.

SOURCE Cephalon, Inc.

http://www.cephalon.com

In a notice letter to Cephalon, Watson contends that Cephalon's patents for the drug are "invalid, unenforceable and/or will not be infringed by Watson's manufacture." Watson said it believes it may be the first applicant to file an ANDA for Fentora containing a paragraph IV certification under the provisions of the Hatch-Waxman Act and, should its product be approved, may be entitled to 180 days of generic market exclusivity.

Corona, California-based Watson Pharmaceuticals is a specialty pharmaceutical company that develops, manufactures, markets, sells and distributes brand and generic pharmaceutical products.

FinancialWire" is a fully independent, proprietary news wire service of Investrend Information (a division of Investrend Communications, Inc.). FinancialWire" news is written by professional journalists, dedicated to pure journalistic standards. FinancialWire" does not receive or accept any compensation from any individual or subject company (or representative thereof) for its news or opinions. All FinancialWire" news is available at http://www.financialwire.net . Please address any inquiries to feedback@financialwire.net .

Free annual reports for companies mentioned in the news are available at http://investrend.ar.wilink.com/?level=279 .

http://www.financialwire.net

In its notice letter to Cephalon, Watson contends that US patents of the product are invalid, unenforceable and/or will not be infringed by Watson's manufacture, use or sale of the product described in its abbreviated new drug application (ANDA). Based on available information, Watson believes it may be the first applicant to file an ANDA for Fentora containing a paragraph IV certification under the provisions of the Hatch-Waxman Act and, should its product be approved, may be entitled to 180 days of generic market exclusivity.

http://www.datamonitor.com

Republication or redistribution, including by framing or similar means,
is expressly prohibited without prior written consent. Datamonitor shall 
not be liable for errors or delays in the content, or for any actions 
taken in reliance thereon

"We are proud to support the development of the brain exhibit and hope that it will inspire an interest in science among young museum visitors. As a scientist, I find it particularly important that children become aware of the scientific discoveries that shape their world at such a formative stage of their lives," said Cephalon CEO and Chairman, Frank Baldino, Jr., PhD. "In addition, I believe in our responsibility as a corporation to contribute to the community in ways that will help ensure that future generations are educated and more prepared to lead the global economy."

"We are tremendously grateful for Cephalon's remarkable $4,000,000 commitment to our neuroscience exhibit," said Dr. Dennis Wint, President and CEO of The Franklin Institute. "We are thrilled to partner with a company with such a deep commitment to science education when it is so very clear that science education is absolutely vital to building a strong, sustainable community."

Both today's seminar and the new exhibit explore how cutting-edge research is changing our view of how the brain functions. Where once the adult brain was considered fixed, scientists are now finding that the brain has an amazing capacity for growth, pointing to new strategies for treating brain diseases or injuries. Where once there was an argument between the respective influences of nature and nurture, the mapping of the human genome has shed new light on how much of our behavior might actually be encoded in our DNA.

The neuroscience exhibit will be housed in a building extension, which not only creates additional signature exhibit space, but will feature climate control capabilities and other features that will allow the museum to remain competitive in drawing blockbuster traveling exhibits to Philadelphia. The neuroscience exhibit will open in late 2012.

The Franklin has doubled its attendance in the last five years. Upgraded facilities, which range from a re-built Giant Heart to a 5,000 square foot store to blockbuster exhibits like Titanic, BodyWorlds and Tut have generated unprecedented attention and audiences. The sum total economic impact to the Philadelphia region of the three blockbusters has been calculated to be over $200 million. To capitalize on the re-invigorated image of the museum, as well as leverage its core mission of inquiry, The Franklin recently introduced its tagline "Curious?" to cement public perceptions of The Franklin as a place for excitement, intrigue and just plain fun.

The Franklin Institute

Increasingly a "go-to" destination, The Franklin is known for blockbuster exhibits, one-of-a-kind theatrical experiences, a growing roster of evening events for adults, and cutting-edge community learning (including a high school partnership with the School District of Philadelphia) with national influence. All are aimed at explaining science in ways that impact on people's lives. Additionally, the museum's prestigious Franklin Awards, which honor the greatest men and women of science, engineering, and technology, has achieved international significance in recent years. The Franklin is considered one of the great science centers in the nation and the world - with the ability to present science in an engaging and increasingly interactive setting that creates real-world relevance to the multi-cultural community which The Franklin serves.

Founded in honor of America's first scientist, Benjamin Franklin, The Franklin Institute is a renowned and innovative leader in the field of science and technology learning, as well as a dynamic center of activity. It is dedicated to creating a passion for science by offering new and exciting access to science and technology in ways that would dazzle and delight its namesake. For more information, please visit www.fi.edu.

SOURCE: The Franklin Institute

The Franklin Institute
Kat Stein, 215-448-2375